NW BIO Announces Completion of DCVAX®-DIRECT Phase I Trial Recruitment

DCVax®-Direct Phase II Trial Preparations and Manufacturing Expansion Underway July 16, 2014 Northwest Biotherapeutics (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the Phase I portion of the Company’s Phase I/II DCVax-Direct clinical trial has completed its 36-patient target recruitment, and the Company is now underway with preparations for the Phase …